sgn-30
mAbexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jan 13, 2003 (NCT00051597)
Timeline
Indications
Mechanism of action
TNFRSF8 agonist
After binding to CD30, this agent interferes with the G1 phase of the cell cycle, thereby inducing growth arrest and apoptosis in susceptible tumor cell populations.
TNFRSF8 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109256 ↗
Also known as
- monoclonal antibody sgn-30
- monoclonal antibody sgn-30
- sgn-30
- sgn-30
- sgn-30
- sgn-30 monoclonal antibody
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00354107 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2007 | National Cancer Institute (NCI) |
| NCT00365274 | Phase 2 | Aug 1, 2006 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT00337194 | Phase 2 | Apr 1, 2006 | Cancer and Leukemia Group B (CALGB), National Cancer Institute (NCI) |
| NCT00099255 | Phase 2 | Sep 1, 2004 | Seattle Genetics |
| NCT00079755 | Phase 2 | Feb 1, 2004 | Seattle Genetics |
| NCT00051597 | Phase 1/Phase 2 (Phase 2) | Jan 13, 2003 | Seattle Genetics |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 3 | 1 | 2006 |
| Seattle Genetics | For profit | 3 | 3 | 1 | 2003 |
| Cancer and Leukemia Group B (CALGB) | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1